A61K 51/06
Macromolecular compounds , carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric
Official title: Macromolecular compounds {, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules (peptides, proteins, polyamino acids A61K51/08; antibodies A61K51/10)}
A61K51/06 (Macromolecular compounds , carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric) appears on 255 US grants and 411 published applications in this corpus.
Search patents in A61K- Granted patents
- 255
- Published applications
- 411
- Assignees
- 250
- Inventors
- 928
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 6 | 0 |
| 1995 | 4 | 0 |
| 1996 | 4 | 0 |
| 1997 | 7 | 0 |
| 1998 | 4 | 0 |
| 1999 | 6 | 0 |
| 2000 | 5 | 0 |
| 2001 | 12 | 5 |
| 2002 | 7 | 8 |
| 2003 | 6 | 18 |
| 2004 | 3 | 10 |
| 2005 | 8 | 10 |
| 2006 | 7 | 8 |
| 2007 | 3 | 10 |
| 2008 | 2 | 8 |
| 2009 | 2 | 4 |
| 2010 | 0 | 12 |
| 2011 | 3 | 12 |
| 2012 | 5 | 11 |
| 2013 | 8 | 19 |
| 2014 | 9 | 19 |
| 2015 | 15 | 22 |
| 2016 | 9 | 18 |
| 2017 | 16 | 24 |
| 2018 | 13 | 21 |
| 2019 | 12 | 22 |
| 2020 | 14 | 19 |
| 2021 | 13 | 24 |
| 2022 | 12 | 26 |
| 2023 | 3 | 20 |
| 2024 | 11 | 23 |
| 2025 | 7 | 25 |
| 2026 | 9 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- DOTA-hapten compositions for anti-DOTA/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy25 Aug 2026US 12,714,758 B2Memorial Sloan Kettering Cancer Center
- Cleavable radioligands for targeting cell surface receptors and uses thereof7 Jul 2026US 12,673,122 B2Full-Life Technologies UK Limited
- Cross-linking compounds and methods of use thereof30 Jun 2026US 12,668,646 B2North Carolina State University
- Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies23 Jun 2026US 12,661,417 B2Cornell University
- Peptide receptor radionuclide therapy9 Jun 2026US 12,649,008 B2The Regents of the University of California
- Development of a platform to noninvasively image car t cells8 Oct 2026US 2026/0306681 A1Dana-Farber Cancer Institute, Inc.
- Cleavable radioligands for targeting cell surface receptors and uses thereof1 Oct 2026US 2026/0295099 A1Full-Life Technologies UK Limited
- Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies17 Sep 2026US 2026/0273111 A1Cornell University
- Compositions and methods for targeting tumor-associated macrophages13 Aug 2026US 2026/0232850 A1Resolute Science
- Conjugates having antifouling nanoparticles and methods of use9 Jul 2026US 2026/0191997 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Radioactive embolizing compositions503US 6,015,541 AMicro Therapeutics, Inc. · 2000
- Method of local radiotherapy by polymerizing a material in vivo to form a hydrogel283US 5,942,209 AFocal, Inc. · 1999
- Polychelating agents for image and spectral enhancement (and spectral shift)138US 5,155,215 AAccess Pharmaceuticals, Inc. · 1992
- System for targeted delivery of therapeutic agents127US 8,709,483 B2Massachusetts Institute of Technology · 2014
- Water soluble paclitaxel derivatives122US 6,730,699 B2PG-TXL Company, L. P. · 2004